Document Detail


A structured literature review of the direct costs of adult systemic lupus erythematosus in the US.
MedLine Citation:
PMID:  21584945     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: A structured review of the literature was undertaken to examine the direct costs of adult systemic lupus erythematosus (SLE) in a US population.
METHODS: English-language studies published from January 2000 to April 2010 were systematically reviewed from both Medline's PubMed and the Cochrane databases. Studies were included if they reported direct medical costs of SLE among adults in the US.
RESULTS: Seven studies published since January 2000 that reported direct medical costs associated with SLE in the US were identified. Studies examined main cost categories of inpatient, outpatient, and pharmacy services; each contributed substantially to total costs. Wide SDs were reported, consistent with variability in disease manifestation. Mean annual direct costs of SLE patients ranged from $13,735-$20,926; the costs of those with and without nephritis ranged from $29,034-$62,651 and $12,273-$16,575, respectively. Across studies of a general SLE population, pharmaceutical costs composed 19-30% of total expenditures, with inpatient costs accounting for 16-50% and outpatient costs accounting for 24-56% of overall costs. Methodologies varied across studies, with patient self-reported resource utilization generating the lowest estimates versus claims-based analyses; Medicaid claims analyses generated lower incremental cost estimates for SLE patients versus control patients compared to estimates based on commercial claims analysis.
CONCLUSION: SLE is associated with substantial annual direct cost burden in the US; however, little research has been done examining costs associated with specific treatments or cost variation by disease severity and disease manifestations. Future research elucidating the causes in variation of costs will help in the appraisal of emerging therapies and in developing clinical management strategies.
Authors:
Katherine A Slawsky; Ancilla W Fernandes; Lauren Fusfeld; Susan Manzi; Thomas F Goss
Related Documents :
16351555 - Remote physiological monitoring: clinical, financial, and behavioral outcomes in a hear...
18831745 - Effects of self-management, education and specific exercises, delivered by health profe...
20528345 - Socioeconomic impact of work-related asthma.
6358325 - Educational self-help approaches in childhood asthma.
20549725 - Tips for success: fostering a good mentoring relationship.
3638185 - Adoxi-plot: a computer program for plotting pedigrees illustrating autosomal dominant a...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Arthritis care & research     Volume:  63     ISSN:  2151-4658     ISO Abbreviation:  Arthritis Care Res (Hoboken)     Publication Date:  2011 Sep 
Date Detail:
Created Date:  2011-09-08     Completed Date:  2011-10-31     Revised Date:  2011-12-09    
Medline Journal Info:
Nlm Unique ID:  101518086     Medline TA:  Arthritis Care Res (Hoboken)     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1224-32     Citation Subset:  IM    
Copyright Information:
Copyright © 2011 by the American College of Rheumatology.
Affiliation:
Boston Healthcare Associates, Inc., Massachusetts 02110, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Ambulatory Care / economics
Drug Costs
Health Care Costs*
Health Expenditures*
Hospital Costs
Humans
Lupus Erythematosus, Systemic / diagnosis,  drug therapy,  economics*
Lupus Nephritis / diagnosis,  drug therapy,  economics*
Models, Economic
United States

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Characteristics of the arthropathy described in hereditary haemochromatosis.
Next Document:  Brief index of lupus damage: a patient-reported measure of damage in systemic lupus erythematosus.